DHS 75.59(3)(b)(b) “Central registry” means an organization that obtains patient identifying information from 2 or more OTPs about individuals applying for maintenance treatment or detoxification treatment for the purpose of preventing an individual’s concurrent enrollment in more than one program. DHS 75.59(3)(c)(c) “Clinical probation” means the period of time determined by the treatment team that a patient is required to increase frequency of service attendance due to rule violations. DHS 75.59(3)(d)(d) “Guest dose” means administration of a medication used for the treatment of opioid addiction to a person who is not a client of the program that is administering or dispensing the medication. DHS 75.59(3)(e)(e) “Initial dosing” means the first administration of methadone or other FDA-approved medication for the treatment of opioid use disorder to relieve a degree of withdrawal and drug craving of the patient. DHS 75.59(3)(f)(f) “Maintenance treatment” means the dispensing of a narcotic drug in the treatment of an individual for opioid dependence. DHS 75.59(3)(g)(g) “Mandatory schedule” means the required dosing schedule for a patient and the established frequency that the patient must attend the service. DHS 75.59(3)(h)(h) “Medically-supervised withdrawal” means dispensing, administering, or prescribing of an FDA-approved medication for the treatment of opioid use disorder in gradually decreasing doses to alleviate adverse physical or psychological effects incident to withdrawal from the continuous or sustained use of opioid drugs. The purpose of medically supervised withdrawal is to bring a patient maintained on maintenance medication to a medication-free state within a target period. DHS 75.59(3)(i)(i) “Medication unit” means a facility established as part of a service but geographically separate from the service, from which licensed private practitioners and community pharmacists are: DHS 75.59(3)(j)(j) “Objectively intoxicated person” means a person who is determined through a breathalyzer test to be under the influence of alcohol. DHS 75.59(3)(k)(k) “Opioid addiction” means psychological and physiological dependence on an opiate substance, either natural or synthetic, that is beyond voluntary control. DHS 75.59(3)(L)(L) “Patient identifying information” means the name, address, social security number, photograph or similar information by which the identity of a patient can be determined with reasonable accuracy and speed, either directly or by reference to other publicly available information. DHS 75.59(3)(n)(n) “Potentiation” means the increasing of potency and, in particular, the synergistic action of two or more drugs which produces an effect that is greater than the effect of each drug used alone. DHS 75.59(3)(o)(o) “SAMHSA” means the Substance Abuse and Mental Health Services Administration. DHS 75.59(3)(p)(p) “Service physician” means a physician licensed to practice medicine in the jurisdiction in which the service is located, and knowledgeable in addiction treatment, who assumes responsibility for the administration of all medical services performed by the OTP including ensuring that the service is in compliance with all federal, state and local laws relating to medical treatment of an opioid use disorder with an FDA approved medication for the treatment of an opioid use disorder. DHS 75.59(3)(q)(q) “Program sponsor” means the person named in the application for certification described in 42 CFR 8.11 (b) who is responsible for the operation of the OTP and who assumes responsibility for all its employees, including any practitioners, agents, or other persons providing medical, rehabilitative, or counseling services at the program or any of its medication units. The program sponsor need not be a licensed physician but shall employ a licensed physician for the position of medical director. The program sponsor is responsible for ensuring the service is in continuous compliance with all federal, state, and local laws and regulations. DHS 75.59(3)(r)(r) “State opioid treatment authority” (SOTA) means the subunit of the department designated by the governor to exercise the responsibility and authority in this state for governing the treatment of a narcotic addiction with a narcotic drug. DHS 75.59(3)(s)(s) “Take-homes” means medications such as methadone that reduce the frequency of a patient’s service visits and with the approval of the service physician, are dispensed in an oral form and are in a container that at a minimum discloses the treatment service name, address and telephone number and the patient’s name, the dosage amount and the date on which the medication is to be ingested. DHS 75.59(3)(t)(t) “Treatment contracting” means an agreement developed between the primary counselor or the clinic director and the patient in an effort to allow the patient to remain in treatment on condition that the patient adheres to service rules. DHS 75.59(3)(u)(u) “Treatment team” means a team established to evaluate the progress of a patient and consisting of at least the primary counselor, the service staff nurse who administers doses and the clinic director. DHS 75.59(4)(4) State Opioid Treatment Authority. The powers and duties of the SOTA include: DHS 75.59(4)(a)(a) Facilitating the development and implementation of rules, regulations, standards, and evidence-based practices, emerging best practices, or promising practices, to ensure the quality of services delivered by OTPs. DHS 75.59(4)(b)(b) Monitoring and evaluation of program outcomes for service recipients and the community. The SOTA may establish or follow already established performance indicators by accrediting bodies or SAMHSA including improvement in medical condition, recidivism rates, and such other measures as appropriate. DHS 75.59(4)(c)(c) Acting as a liaison between relevant state and federal agencies. DHS 75.59(4)(d)(d) Reviewing opioid treatment guidelines and regulations developed by the federal government. DHS 75.59(4)(e)(e) Delivering technical assistance and informational materials to OTPs as needed. DHS 75.59(4)(f)(f) Performing both scheduled and unscheduled site visits to OTPs in cooperation with department certification office or other oversight agencies, or as designated by the SOTA, when necessary and appropriate, and preparing reports as appropriate to assist the department’s certification office or to meet the requirements set forth in s. 51.4223, Stats.